| E. Kevin Hrusovsky |
E. Kevin Hrusovsky is the founder and currently holds the position of Chairman at Powering Precision Health, which was founded in 2014. He is also currently the Chairman at 908 Devices, Inc. since 2013, Director at Solect Technology Group, Inc., Director at Cell Signaling Technology, Inc., Director at Society for Laboratory Automation & Screening since 2003, Independent Director at DA32 Life Science Tech Acquisition Corp. since 2021, Venture Partner at ARCH Venture Partners LLC since 2023, and Member-Educational Board at Massachusetts Biotechnology Council. In his former positions, Mr. Hrusovsky served as President, Chief Executive Officer & Director at Caliper Life Sciences, Inc. from 2003 to 2011, President, Chief Executive Officer & Director at Zymark Corp. from 1996 to 2003, Executive Chairman at Quanterix Corp. from 2014 to 2022, Director at Xenogen Corp. from 2004 to 2006, Director at SeraCare Life Sciences, Inc., Director at UroMedica, Inc., Director at Association for Laboratory Automation, Director at SynapDx Corp. from 2013 to 2017, Director at Alliant Medical Technologies, Director at BioIVT LLC from 2016 to 2021, Director at Solect Energy Development LLC, Director at Cellaria Biosciences LLC from 2015 to 2019, Head-North American Sales & Marketing at EIDP, Inc. from 1983 to 1992, Head-International Agricultural Products at FMC Corp. from 1992 to 1996, Senior VP, President-Life Sciences & Technology at Revvity, Inc. from 2011 to 2013, President at Revvity Oy from 2011 to 2013, and Manager at DuPont from 1984 to 1992. Mr. Hrusovsky obtained an undergraduate degree from The Ohio State University in 1983 and an MBA from The Ohio University in 1988. |
| Christopher D. Brown |
Christopher D. Brown is the founder. He founded 908 Devices, Inc. in 2012 and currently holds the title of Chief Product Officer. Dr. Brown's former job includes working as a Senior Director-Engineering & Product Development at Thermo Fisher Scientific, Inc. in 2010. He also worked as a Platform Architect at Apple, Inc. and as the Head-Product Development & Engineering at Ahura Scientific, Inc. from 2004 to 2010. Additionally, he held the position of Manager-Modeling & Spectroscopy at InLight Solutions, Inc. In terms of education, Dr. Brown completed his undergraduate degree at Brandon University and obtained a doctorate from Dalhousie University. |
| Joseph H. Griffith |
Joseph H. Griffith is currently the Chief Financial Officer & Treasurer at 908 Devices, Inc. Prior to his current position, he served as the Chief Financial Officer-Life Sciences & Technology at Revvity, Inc. from 2011 to 2014. Before that, he worked as an Audit Senior at Arthur Andersen LLP from 1997 to 2002, as a Controller at Zymark Corp. from 2002 to 2003, and as the Chief Accounting Officer & Vice President-Finance at Caliper Life Sciences, Inc. from 2003 to 2011. Mr. Griffith obtained his undergraduate degree from Villanova University. |
| Kevin J. Knopp |
Kevin J. Knopp is the founder. He founded Ahura Scientific, Inc. in 2002 and held the title of Senior Vice President. He also founded 908 Devices, Inc. in 2012 and currently holds the titles of President, Chief Executive Officer & Director. In addition to his founding positions, Dr. Knopp has held former job positions. He worked as a Director at Crystal IS, Inc. in 2011 and as Vice President & Site Leader at Thermo Fisher Scientific, Inc. from 2010 to 2011. Dr. Knopp's education history includes an undergraduate degree from Boston University and graduate and doctorate degrees from The University of Colorado, both conferred in 1999. |
| Fenel M. Eloi |
Fenel M. Eloi is currently an Independent Director at Standard BioTools, Inc., 908 Devices, Inc., Ultivue, Inc., and a Director at Vaxess Technologies, Inc. He is also a Director at Mitotherapeutix LLC, Complete Care IT LLC, Museum of Science, and a Managing Partner at P&M Capital Partners LLC. Previously, he worked as a Director at BioHelix Corp. from 2009 to 2013, Chief Financial Officer at Oscient Pharmaceuticals Corp. from 1989 to 1991, Chief Financial Officer & Senior Vice President at LifeCell Corp., Principal at Haemonetics Corp., and Chief Operating & Financial Officer at Interleukin Genetics, Inc. He also served as the Chief Operating & Financial Officer at Cell Signaling Technology, Inc. from 2006 to 2018. Mr. Eloi holds an MBA from Anna Maria College and an undergraduate degree from Lee University. |
| Marcia T. Eisenberg |
Dr. Marcia T. Eisenberg is an Independent Director at Singular Genomics Systems, Inc., an Independent Director at 908 Devices, Inc., a Chief Scientific Officer-Enterprise at Laboratory Corp. of America Holdings and a Member of Federal Bureau of Investigation. She is on the Board of Directors at Singular Genomics Systems, Inc., 908 Devices, Inc. and OmniSeq, Inc. She received her undergraduate degree from State University of New York at Albany, a graduate degree from State University of New York at Albany and a doctorate degree from the University of Kentucky. |
| Tony J. Hunt |
Tony J. Hunt is currently the Chief Executive Officer & Director at Repligen Corp. since 2023 and an Independent Director at 908 Devices, Inc. since 2022. Previously, he held the position of Senior Director-Pharma Programs at Applied Biosystems, Inc. from 2000 to 2008 and President-Bioproduction at Life Technologies Corp. from 2011 to 2014. Mr. Hunt completed his undergraduate and graduate degrees at the National University of Ireland and holds an MBA from the Questrom School of Business. |
| Keith L. Crandell |
Keith L. Crandell founded ARCH Venture Partners LLC in 1986, where he is working as Managing Director from 2010. Mr. Crandell also currently works at 908 Devices, Inc., as Independent Director from 2012, Cytrellis Biosystems, Inc., as Director, Twist Bioscience Corp., as Independent Director from 2013, Alfalight, Inc., as Director, PixelEXX Systems, Inc., as Director, Cubs Rainbow, Inc., as Director, Evergreen Climate Innovation, as Director, Ultivue, Inc., as Director, Arbor Biotechnologies, Inc., as Director, Genturi, Inc., as Director, Lightcast Discovery Ltd., as Director, Scale Biosciences, Inc., as Director, DA32 Life Science Tech Acquisition Corp., as Director from 2021, Airna, Inc., as Director, and Chicago History Museum, as Trustee. Mr. Crandell also formerly worked at Apropos Technology, Inc., as Director, Illumina, Inc., as Director, Nanosys, Inc., as Director, Celebrate Express, Inc., as Director from 2002 to 2008, Crystal IS, Inc., as Director, Adesto Technologies Corp., as Independent Director from 2007 to 2019, Quanterix Corp., as Independent Director from 2007 to 2023, Boreal Genomics, Inc., as Director, MicroOptical Devices, Inc., as Director, Univa Corp., as Director, National Venture Capital Association, as Director, Illinois Venture Capital Association, as Director, MobileVerbs, Inc., as Director, Permeon Biologics, Inc., as Director, Quantum Circuits, Inc., as Director, Mass SAS, as Director, Hercules, Inc., as Principal, ISCO International, Inc., as Principal, Nanophase Technologies Corp., as Principal, Eichrom Technologies LLC, as Principal, Alis Corp., as Principal, ARCH Development Corp., as Senior Manager, The Morton Arboretum, Inc., as Trustee, and Polsky Center For Entrepreneurship & Innovation, as Advisor. Mr. Crandell received his Masters Business Admin degree from The University of Chicago, undergraduate degree from St. Lawrence University, and graduate degree from The University of Texas at Arlington. |
| Jeffrey P. George |
Jeffrey P. George is currently the Chairman at LENZ Therapeutics, Inc., Chairman at Lykos Therapeutics, Inc., Chairman at Education Opens Doors, Inc., Director at Dorian Therapeutics, Inc., Independent Director at Amneal Intermediate, Inc., Independent Director at Amneal Pharmaceuticals, Inc., Director at Young Presidents' Organization, Dallas Chapter, Independent Director at 908 Devices, Inc., Director at North Texas Food Bank, Operating Advisor at Revival Healthcare Capital LLC, Partner at Bridge Builders Collaborative, and Managing Partner at Maytal Capital LLC. He previously served as the Chief Executive Officer & Director at Performance Health Holdings, Inc., Chief Executive Officer at Alcon AG, Chairman at Ypo, Inc., Director at WishBone Medical, Inc., Director at Roam Analytics, Inc., Senior Director-Strategy & Business Development at Gap, Inc., Head-Sandoz Division at Novartis AG, Head-Emerging Markets at Novartis Pharmaceuticals Corp., and Engagement Manager at McKinsey & Co., Inc. Mr. George holds an MBA degree from Harvard Business School, a graduate degree from The Johns Hopkins University, and an undergraduate degree from Carleton College. |
| Mark D. Spoto |
Mark D. Spoto is currently an Independent Director at 908 Devices, Inc., a Director at BlackSky Holdings, Inc. (Virginia), a Director at Mersive Technologies, Inc., a Managing Director at Razor's Edge Ventures LLC, a Director at Ursa Space Systems, Inc., a Director at HawkEye 360, Inc., a Director at BlackSky Global LLC, and a Director at X-Bow Launch Systems, Inc. In the past, Mr. Spoto worked as an Associate at Hunton & Williams LLP, a Principal at Cooley Godward LLP, an Associate at Latham & Watkins LLP, a Partner at Cooley LLP, and an Aerospace Engineer at Mcdonnell Douglas Space Systems Co. Mr. Spoto received an undergraduate degree from Boston University and a graduate degree from Georgetown University Law Center. |
